You are here

Contact:
Mark E. Brager
202-434-7244
mbrager@advamed.org
April 20, 2015

AdvaMed Statement on Introduction of Trade Promotion Bill

WASHINGTON, D.C. – Stephen J. Ubl, president and CEO of the Advanced Medical Technology Association (AdvaMed), issued the following statement on the introduction of bipartisan legislation in the Senate and House to modernize and renew Trade Promotion Authority (TPA):

“AdvaMed strongly commends Senate Finance Committee Chairman Orrin Hatch (R-Utah), Ranking Member Ron Wyden (D-Ore.) and House Ways and Means Committee Chairman Paul Ryan (R-Wis.) for their work in developing bipartisan legislation which will allow America’s medical technology companies to provide life-changing innovations to more patients worldwide while helping one of the drivers of the U.S. economy continue to grow.

“The medical technology sector is one of the few American manufacturing industries that maintains a positive balance of trade, with $42 billion in U.S. exports. International markets offer tremendous opportunities for additional growth:  the medical technology markets in India, China, Japan and Europe are already worth more than $150 billion each year.

“Continued industry growth outside the U.S. will depend on the development and approval of trade agreements that provide a level-playing field for U.S. companies and improve access to the global market.

“The U.S. Trade Representative is currently working to advance priority issues for the medical technology industry as part of the Trans-Pacific Partnership (TPP) and the Transatlantic Trade and Investment Partnership (TTIP), both of which will greatly improve market access to medical technology in these regions. The TPA legislation introduced today will help make sure these agreements come to fruition and ensure that the U.S. has a prominent seat at the table when future free trade agreements are negotiated.

“Of significance in the bipartisan TPA bill is a principle negotiating objective to improve regulatory practices through transparency and procedural fairness in medical technology reimbursement. This provision will aim to increase transparency and opportunity for the participation of stakeholders in the development of regulations and ensure that government regulatory reimbursement regimes are transparent, ensure procedural fairness and provide full market access for U.S. products. Similar provisions are included in the U.S.-Korea Free Trade Agreement.

“We urge Congress to move forward with this important legislation, and we are committed to working with members of Congress, the administration and other stakeholders to ensure its enactment.”

# # #